Treating atrial fibrillation at the origin.


AtriAN uses Pulsed Field Ablation (PFA) to ablate neuronal cells selectively.
As a result, the other tissues, such as healthy heart muscle, are spared.


Most ablation techniques use either heat (burning) or cold (freezing) to ablate tissue with an intent to create scar tissue which damage surrounding healthy tissues. Our PFA is non-thermal.


Our unique approach of targeting neuronal cells in clusters known as ganglionated plexi (GPs) should prove, from a “first principles” approach to provide a more durable solution.

Mission & Vision

Resolving Atrial Fibrillation at its origin

Current therapies are failing patients and their physicians. Medication fails 70% of the time, and ablations fail 30% within the first year and 50% within three. We are targeting the cardiac autonomic nervous system which should lead to a more durable solution significantly reducing the need for repeat procedures.


A Disruptive Approach to Rhythm restoration

AtriAN combines two approaches to the long-term resolution of Atrial Fibrillation. First, we navigate to the heart’s epicardial (outside) surface, where the errant signals originate in specialized neurons. Secondly, we use new and non-thermal energy (PFA) to disable the neurons permanently.


AtriAN’s Business Pathway

Growing Market

Atrial Fibrillation is a large and quickly growing condition. Unfortunately, there is yet to be a perfect solution for its resolution. AtriAN’s mission is to change this for patients and their physicians.

Robust and Innovative Intellectual Property (IP)

The idea and technology were conceived and first developed at the Mayo Clinic (Rochester, MN, USA) by Dr. Sam Asirvatham with issued patents across the globe. We continue to innovate the technology.

Unique Solution

AtriAN takes a novel and unique approach to the resolution of the disease by targeting and disabling the hyperactive signals responsible for the arrhythmia.

Funding in Place

AtriAN has raised over €5M in funding, bringing us to that exciting stage of first clinical treatments. We are seeking expressions of interest from investors for the next phase of our journey.

Unmet Need

Existing medications have a very high failure rate and affect every organ in the body. Current ablation technologies only seek to block the signals responsible for this condition; this results in recurrence rates that are far too high.

First In Human (FIH) Trials

AtriAN is excited to announce that we have enrolled and treated 36 patients in two First-In-Human (FIH) trials.

R & D

Research & Development

In addition to our work with Pulsed Field Ablation (PFA), we are progressing our R&D with innovative, unique and minimally-invasive catheters to reach and deliver the energy to the epicardial surface of the heart.

Pulsed Field Ablation (PFA)

This energy is revolutionising the field of electrophysiology due to its safety profile. While most companies replace thermal energy with PFA, on the inside of the heart (endocardial) AtriAN takes it directly to the condition’s origin on the outside (epicardially).

Autonomics Remodeling

Neuromodulation has been one of the most exciting and disruptive approaches to medicine in recent years. Our approach is to restore the autonomic tone of the heart by targeting and disabling the ganglionated plexi (GP) structures.

Sub-Xiphoid Approach

We are using a unique, small incision in the sub-xiphoid region using our small IP-protected catheters.

Get Started

Work with Us

If you have an interest in helping AtriAN bring this revolutionary and disruptive treatment to patients world-wide, please contact us.